Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22749218 | 0.83 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2NPC1RAB9ACYP1A2 | |
| SCHEMBL10284047 | 0.81 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2NPC1RAB9ACYP1A2 | |
| SCHEMBL14620595 | 0.77 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2NPC1RAB9ACYP1A2 | |
| SCHEMBL30987861 | 0.77 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2NPC1RAB9ACYP1A2 | |
| SCHEMBL757021 | 0.76 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2NPC1RAB9ACYP1A2 | |
| SCHEMBL14588673 | 0.75 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2NPC1RAB9ACYP1A2 | |
| SCHEMBL14620598 | 0.75 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2NPC1RAB9ACYP1A2 | |
| SCHEMBL1562841 | 0.74 | HPSE (0.60) | ALDH1A1SMN1; SMN2NPC1RAB9ACYP1A2 | |
| SCHEMBL29394827 | 0.74 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2NPC1RAB9ACYP1A2 | |
| SCHEMBL76069 | 0.74 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2NPC1RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2888284-B1 | ANTIBODIES TO RISPERIDONE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-06 | — | — | EP | disclosed |
| US-11226345-B2 | Antibodies to olanzapine haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-18 | — | — | US | disclosed |
| US-11225527-B2 | Antibodies to paliperidone haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-18 | — | — | US | disclosed |
| US-20210017294-A9 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-21 | — | — | US | disclosed |
| US-20200399400-A1 | ANTIBODIES TO RISPERIDONE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-24 | — | — | US | disclosed |
| CN-111770930-A | Method for producing peptide | 苏尔福工具股份有限公司 | 2020-10-13 | — | — | CN | disclosed |
| US-10793644-B2 | Antibodies to risperidone haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-06 | — | — | US | disclosed |
| US-10712353-B2 | Antibodies to olanzapine haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-14 | — | — | US | disclosed |
| EP-3385284-B1 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-26 | — | — | EP | disclosed |
| US-20200040107-A1 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-06 | — | — | US | disclosed |
| US-20140057305-A1 | Antibodies to Quetiapine Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057301-A1 | Antibodies to Risperidone Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057297-A1 | Antibodies to Paliperidone Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057301-A1 | Antibodies to Risperidone Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057297-A1 | Antibodies to Paliperidone Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057303-A1 | Antibodies to Olanzapine Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057303-A1 | Antibodies to Olanzapine Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057305-A1 | Antibodies to Quetiapine Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| CN-103012319-A | Repaglinide intermediate synthesis process improvement | ZHEJIANG JIUZHOU PHARM CO LTD | 2013-04-03 | — | — | CN | disclosed |
| WO-2007092196-A2 | COMPOSITIONS AND METHODS FOR TREATING MYELOID PROLIFERATIVE DISORDERS | CELLERANT THERAPEUTICS, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793644-B2 | Antibodies to risperidone haptens and use thereof | HTR4, HTR3C, OPRL1 | ALDH1A1 2023/4885SMN1; SMN2 3228/4885NPC1 2941/4885 |
| US-11225527-B2 | Antibodies to paliperidone haptens and use thereof | LY96, OPRL1, HTR3C | ALDH1A1 1562/4885SMN1; SMN2 3778/4885NPC1 3180/4885 |
| US-11226345-B2 | Antibodies to olanzapine haptens and use thereof | HTR4, HTR3C, HTR1A | ALDH1A1 1968/4885SMN1; SMN2 4333/4885NPC1 2954/4885 |
| US-20140057305-A1 | Antibodies to Quetiapine Haptens and Use Thereof | HTR4, HTR3C, SLC6A4 | ALDH1A1 2245/4885SMN1; SMN2 4622/4885NPC1 2379/4885 |
| US-20140057301-A1 | Antibodies to Risperidone Haptens and Use Thereof | HTR4, HTR3C, OPRL1 | ALDH1A1 2023/4885SMN1; SMN2 3228/4885NPC1 2941/4885 |
| US-10712353-B2 | Antibodies to olanzapine haptens and use thereof | HTR4, HTR3C, HTR1A | ALDH1A1 1968/4885SMN1; SMN2 4333/4885NPC1 2954/4885 |
| US-20200399400-A1 | ANTIBODIES TO RISPERIDONE HAPTENS AND USE THEREOF | HTR4, HTR3C, OPRL1 | ALDH1A1 2023/4885SMN1; SMN2 3228/4885NPC1 2941/4885 |
| US-20200040107-A1 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | HTR4, HTR3C, SLC6A4 | ALDH1A1 2245/4885SMN1; SMN2 4622/4885NPC1 2379/4885 |
| US-20140057303-A1 | Antibodies to Olanzapine Haptens and Use Thereof | HTR4, HTR3C, HTR1A | ALDH1A1 1968/4885SMN1; SMN2 4333/4885NPC1 2954/4885 |
| US-20210017294-A9 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | HTR4, HTR3C, SLC6A4 | ALDH1A1 2245/4885SMN1; SMN2 4622/4885NPC1 2379/4885 |
| US-20140057297-A1 | Antibodies to Paliperidone Haptens and Use Thereof | LY96, OPRL1, HTR3C | ALDH1A1 1562/4885SMN1; SMN2 3778/4885NPC1 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.